136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)
Authors:
- J. MazièresJMJ. Mazières
- 1 April 2018
- journal article
- abstracts
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (4) , S79